Jennifer B Christian

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. pmc HDL-C Response Variability to Niacin ER in US Adults
    Jennifer B Christian
    GlaxoSmithKline, Clinical Effectiveness and Safety, 5 Moore Drive, B 3116, Durham, NC 27709 3398, USA
    Cholesterol 2013:681475. 2013
  2. doi request reprint Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia
    Jennifer B Christian
    Clinical Effectiveness and Safety, GlaxoSmithKline, Durham, NC Electronic address
    Am J Med 127:36-44.e1. 2014
  3. pmc Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction
    Jennifer B Christian
    GlaxoSmithKline, Durham, NC, USA
    Am Heart J 164:846-55. 2012
  4. doi request reprint Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia
    Jennifer B Christian
    Clinical Effectiveness and Safety, GlaxoSmithKline, 5 Moore Drive, B 3116, Durham, NC 27709 3398, USA
    J Clin Lipidol 6:450-61. 2012
  5. doi request reprint Prevalence, characteristics, and risk factors of elevated triglyceride levels in US children
    Jennifer B Christian
    GlaxoSmithKline, Durham, NC, USA
    Clin Pediatr (Phila) 50:1103-9. 2011
  6. doi request reprint Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults
    Jennifer B Christian
    Smith Hanley Consulting Group LLC, Durham, NC, USA
    Am J Cardiol 107:891-7. 2011
  7. doi request reprint Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008
    Jennifer B Christian
    GlaxoSmithKline, Worldwide Epidemiology, Durham, North Carolina, USA
    J Cardiovasc Med (Hagerstown) 12:714-22. 2011
  8. doi request reprint Right answers, wrong questions in clinical research
    Ralph I Horwitz
    Clinical Effectiveness and Safety, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Sci Transl Med 6:221fs5. 2014

Detail Information

Publications8

  1. pmc HDL-C Response Variability to Niacin ER in US Adults
    Jennifer B Christian
    GlaxoSmithKline, Clinical Effectiveness and Safety, 5 Moore Drive, B 3116, Durham, NC 27709 3398, USA
    Cholesterol 2013:681475. 2013
    ..08, P < 0.001) and females (mean HDL-C effect = 0.10, P = 0.019). Conclusion. Baseline HDL-C levels are the biggest predictor of response to niacin ER treatment for both males and females among the factors evaluated...
  2. doi request reprint Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia
    Jennifer B Christian
    Clinical Effectiveness and Safety, GlaxoSmithKline, Durham, NC Electronic address
    Am J Med 127:36-44.e1. 2014
    ..This study evaluates the association between lower follow-up triglyceride levels and incidence of clinical events for patients with severe hypertriglyceridemia...
  3. pmc Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction
    Jennifer B Christian
    GlaxoSmithKline, Durham, NC, USA
    Am Heart J 164:846-55. 2012
    ..We focus on 3 commonly used imaging modalities in the evaluation of cardiac function: echocardiography, magnetic resonance imaging, and radionuclide (nuclear) imaging and highlight areas for future research...
  4. doi request reprint Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia
    Jennifer B Christian
    Clinical Effectiveness and Safety, GlaxoSmithKline, 5 Moore Drive, B 3116, Durham, NC 27709 3398, USA
    J Clin Lipidol 6:450-61. 2012
    ..In this study we investigated the association between patients with severely increased triglycerides whose follow-up triglyceride levels were <500 mg/dL and reduction of important clinical events and associated health care costs...
  5. doi request reprint Prevalence, characteristics, and risk factors of elevated triglyceride levels in US children
    Jennifer B Christian
    GlaxoSmithKline, Durham, NC, USA
    Clin Pediatr (Phila) 50:1103-9. 2011
    ..Fibrates were the most commonly prescribed triglyceride-lowering agent among children with SHTG, followed by statins and Lovaza...
  6. doi request reprint Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults
    Jennifer B Christian
    Smith Hanley Consulting Group LLC, Durham, NC, USA
    Am J Cardiol 107:891-7. 2011
    ..04, 95% CI 1.45 to 6.37), and chronic renal disease (OR 7.32, 95% CI 1.45 to 36.94). In conclusion, SHTG is rare among adults in the United States and the use of pharmacologic intervention is low among those with SHTG...
  7. doi request reprint Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008
    Jennifer B Christian
    GlaxoSmithKline, Worldwide Epidemiology, Durham, North Carolina, USA
    J Cardiovasc Med (Hagerstown) 12:714-22. 2011
    ....
  8. doi request reprint Right answers, wrong questions in clinical research
    Ralph I Horwitz
    Clinical Effectiveness and Safety, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Sci Transl Med 6:221fs5. 2014
    ..To ensure that clinical research arrives at the "right" answers to the right questions for patients, studies should be designed to more closely approximate real-world use of therapeutics and devices. ..